Pharmaceutical Executive Daily: New Research on Ozempic
In the Pharmaceutical Executive Daily, key news includes the FDA approval of Bayer's Lynkuet and research on Ozempic's potential to reduce biological age.
The FDA has approved Bayer's Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms associated with menopause, based on Phase III OASIS trial data.
Lynkuet offers a non-hormonal option, providing an alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: Ozempic may reduce biological age.